Evidence map›Paper›PMID 32632557›Full record

ReviewJournal of thrombosis and thrombolysis2021

Advance of antithrombotic treatment in patients with cerebral microbleed.

Zhiying Chen, Yuchuan Ding, Xunming Ji, Xiaoping Yin, Ran Meng

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of thrombosis and thrombolysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhiying ChenDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
Yuchuan DingDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
Xunming JiDepartment of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Xiaoping YinDepartment of Neurology, Affiliated Hospital of Jiujiang University, Jiujiang, 332000, Jiangxi, China.
Ran MengDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China. victor65@126.com.ORCID http://orcid.org/0000-0001-8452-8758

Funding

National Natural Science Foundation of China 81371289National Natural Science Foundation of China 81660209National Natural Science Foundation of China 81760221
6 · The paper itself

Abstract

With the elder proportion increasing and the antithrombotic agents widely using as well as the newly magnetic resonance imaging sequence emerging, the detection rate of cerebral microbleed (CMB) is gradually raising in recent years. As we all know that CMB mainly reflects the severity of deeply small vessel lesions, which predicts hemorrhagic transformation. Whereby, to some patients with both CMB and remarkable antithrombotic indication, treatment becomes a dilemma. We have to face the challenge of weighing the pros and cons of both drug indication and bleeding risk when making a proper decision for patients. This study summarized recent advance on CMB diagnosis and treatment, to provide a useful reference to physicians in their clinical practice.

Indexed as

Thrombolytic TherapyAnticoagulantsCerebral HemorrhageDisease ManagementHumansIschemic StrokePlatelet Aggregation InhibitorsThrombosisAnticoagulantsPlatelet Aggregation InhibitorsAnticoagulationAntiplateletCerebral microbleedIschemic strokeThrombolysis

Identifiers

PMID32632557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.